-
Je něco špatně v tomto záznamu ?
Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens
A. Cozzi-Lepri, R. Zangerle, L. Machala, K. Zilmer, M. Ristola, C. Pradier, O. Kirk, H. Sambatakou, G. Fätkenheuer, I. Yust, P. Schmid, M. Gottfredsson, I. Khromova, D. Jilich, R. Flisiak, J. Smidt, B. Rozentale, R. Radoi, MH. Losso, JD....
Jazyk angličtina Země Anglie, Velká Británie
Typ dokumentu časopisecké články, práce podpořená grantem
NLK
Free Medical Journals
od 1999 do Před 2 roky
Medline Complete (EBSCOhost)
od 1999-10-01 do Před 1 rokem
Wiley Free Content
od 1999 do Před 2 roky
PubMed
28984429
DOI
10.1111/hiv.12557
Knihovny.cz E-zdroje
- MeSH
- analýza přežití MeSH
- antiretrovirové látky aplikace a dávkování MeSH
- dospělí MeSH
- HIV infekce komplikace farmakoterapie MeSH
- hodnocení rizik MeSH
- incidence MeSH
- lidé středního věku MeSH
- lidé MeSH
- nádory epidemiologie mortalita MeSH
- prospektivní studie MeSH
- raltegravirum kalicum aplikace a dávkování MeSH
- vysoce aktivní antiretrovirová terapie metody MeSH
- Check Tag
- dospělí MeSH
- lidé středního věku MeSH
- lidé MeSH
- mužské pohlaví MeSH
- ženské pohlaví MeSH
- Publikační typ
- časopisecké články MeSH
- práce podpořená grantem MeSH
OBJECTIVES: There are currently few data on the long-term risk of cancer and death in individuals taking raltegravir (RAL). The aim of this analysis was to evaluate whether there is evidence for an association. METHODS: The EuroSIDA cohort was divided into three groups: those starting RAL-based combination antiretroviral therapy (cART) on or after 21 December 2007 (RAL); a historical cohort (HIST) of individuals adding a new antiretroviral (ARV) drug (not RAL) to their cART between 1 January 2005 and 20 December 2007, and a concurrent cohort (CONC) of individuals adding a new ARV drug (not RAL) to their cART on or after 21 December 2007. Baseline characteristics were compared using logistic regression. The incidences of newly diagnosed malignancies and death were compared using Poisson regression. RESULTS: The RAL cohort included 1470 individuals [with 4058 person-years of follow-up (PYFU)] compared with 3787 (4472 PYFU) and 4467 (10 691 PYFU) in the HIST and CONC cohorts, respectively. The prevalence of non-AIDS-related malignancies prior to baseline tended to be higher in the RAL cohort vs. the HIST cohort [adjusted odds ratio (aOR) 1.31; 95% confidence interval (CI) 0.95-1.80] and vs. the CONC cohort (aOR 1.89; 95% CI 1.37-2.61). In intention-to-treat (ITT) analysis (events: RAL, 50; HIST, 45; CONC, 127), the incidence of all new malignancies was 1.11 (95% CI 0.84-1.46) per 100 PYFU in the RAL cohort vs. 1.20 (95% CI 0.90-1.61) and 0.83 (95% CI 0.70-0.99) in the HIST and CONC cohorts, respectively. After adjustment, there was no evidence for a difference in the risk of malignancies [adjusted rate ratio (RR) 0.73; 95% CI 0.47-1.14 for RALvs. HIST; RR 0.95; 95% CI 0.65-1.39 for RALvs. CONC] or mortality (adjusted RR 0.87; 95% CI 0.53-1.43 for RALvs. HIST; RR 1.14; 95% CI 0.76-1.72 for RALvs. CONC). CONCLUSIONS: We found no evidence for an oncogenic risk or poorer survival associated with using RAL compared with control groups.
Centre for HIV AIDS and infectious diseases Kaliningrad Russian Federation
Department of Infectious Diseases and Hepatology Medical University of Bialystok Bialystok Poland
Dr Victor Babes Hospital Bucureşti Romania
Helsinki University Hospital Helsinki Finland
Hospital J M Ramos Mejia Buenos Aires Argentina
Ichilov Hospital Tel Aviv Yafo Israel
Ida Viru Central Hospital Kohtla Jarve
Infectology Center of Latvia Riga Latvia
Ippokration General Hospital Athens Greece
Kantonsspital St Gallen St Gallen Switzerland
L'Archet 1 Hospital University of Nice Sophia Antipolis Nice France
Medical University Innsbruck Innsbruck Austria
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19013066
- 003
- CZ-PrNML
- 005
- 20190409152036.0
- 007
- ta
- 008
- 190405s2018 enk f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1111/hiv.12557 $2 doi
- 035 __
- $a (PubMed)28984429
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a enk
- 100 1_
- $a Cozzi-Lepri, A $u Centre for Clinical Research, Modelling and Epidemiology, Research Department of Infection and Population Health, Institute for Global Health, University College London Medical School, Royal Free Campus, London, UK.
- 245 10
- $a Incidence of cancer and overall risk of mortality in individuals treated with raltegravir-based and non-raltegravir-based combination antiretroviral therapy regimens / $c A. Cozzi-Lepri, R. Zangerle, L. Machala, K. Zilmer, M. Ristola, C. Pradier, O. Kirk, H. Sambatakou, G. Fätkenheuer, I. Yust, P. Schmid, M. Gottfredsson, I. Khromova, D. Jilich, R. Flisiak, J. Smidt, B. Rozentale, R. Radoi, MH. Losso, JD. Lundgren, A. Mocroft, . ,
- 520 9_
- $a OBJECTIVES: There are currently few data on the long-term risk of cancer and death in individuals taking raltegravir (RAL). The aim of this analysis was to evaluate whether there is evidence for an association. METHODS: The EuroSIDA cohort was divided into three groups: those starting RAL-based combination antiretroviral therapy (cART) on or after 21 December 2007 (RAL); a historical cohort (HIST) of individuals adding a new antiretroviral (ARV) drug (not RAL) to their cART between 1 January 2005 and 20 December 2007, and a concurrent cohort (CONC) of individuals adding a new ARV drug (not RAL) to their cART on or after 21 December 2007. Baseline characteristics were compared using logistic regression. The incidences of newly diagnosed malignancies and death were compared using Poisson regression. RESULTS: The RAL cohort included 1470 individuals [with 4058 person-years of follow-up (PYFU)] compared with 3787 (4472 PYFU) and 4467 (10 691 PYFU) in the HIST and CONC cohorts, respectively. The prevalence of non-AIDS-related malignancies prior to baseline tended to be higher in the RAL cohort vs. the HIST cohort [adjusted odds ratio (aOR) 1.31; 95% confidence interval (CI) 0.95-1.80] and vs. the CONC cohort (aOR 1.89; 95% CI 1.37-2.61). In intention-to-treat (ITT) analysis (events: RAL, 50; HIST, 45; CONC, 127), the incidence of all new malignancies was 1.11 (95% CI 0.84-1.46) per 100 PYFU in the RAL cohort vs. 1.20 (95% CI 0.90-1.61) and 0.83 (95% CI 0.70-0.99) in the HIST and CONC cohorts, respectively. After adjustment, there was no evidence for a difference in the risk of malignancies [adjusted rate ratio (RR) 0.73; 95% CI 0.47-1.14 for RALvs. HIST; RR 0.95; 95% CI 0.65-1.39 for RALvs. CONC] or mortality (adjusted RR 0.87; 95% CI 0.53-1.43 for RALvs. HIST; RR 1.14; 95% CI 0.76-1.72 for RALvs. CONC). CONCLUSIONS: We found no evidence for an oncogenic risk or poorer survival associated with using RAL compared with control groups.
- 650 _2
- $a dospělí $7 D000328
- 650 _2
- $a antiretrovirové látky $x aplikace a dávkování $7 D044966
- 650 _2
- $a vysoce aktivní antiretrovirová terapie $x metody $7 D023241
- 650 _2
- $a ženské pohlaví $7 D005260
- 650 _2
- $a HIV infekce $x komplikace $x farmakoterapie $7 D015658
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a incidence $7 D015994
- 650 _2
- $a mužské pohlaví $7 D008297
- 650 _2
- $a lidé středního věku $7 D008875
- 650 _2
- $a nádory $x epidemiologie $x mortalita $7 D009369
- 650 _2
- $a prospektivní studie $7 D011446
- 650 _2
- $a raltegravirum kalicum $x aplikace a dávkování $7 D000068898
- 650 _2
- $a hodnocení rizik $7 D018570
- 650 _2
- $a analýza přežití $7 D016019
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a práce podpořená grantem $7 D013485
- 700 1_
- $a Zangerle, R $u Medical University Innsbruck, Innsbruck, Austria.
- 700 1_
- $a Machala, L $u Department of Infectious and Tropical Diseases, Third Faculty of Medicine, Charles University and Na Bulovce Hospital, Prague, Czech Republic.
- 700 1_
- $a Zilmer, K $u West-Tallinn Central Hospital, Tallinn, Estonia.
- 700 1_
- $a Ristola, M $u Helsinki University Hospital, Helsinki, Finland.
- 700 1_
- $a Pradier, C $u L'Archet 1 Hospital, University of Nice Sophia-Antipolis, Nice, France.
- 700 1_
- $a Kirk, O $u Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
- 700 1_
- $a Sambatakou, H $u Ippokration General Hospital, Athens, Greece.
- 700 1_
- $a Fätkenheuer, G $u Department of Internal Medicine 1, University Hospital of Cologne, Cologne, Germany. German Center for Infection Research (DZIF), Partner Site Bonn-Cologne, Cologne, Germany.
- 700 1_
- $a Yust, I $u Ichilov Hospital, Tel Aviv-Yafo, Israel.
- 700 1_
- $a Schmid, P $u Kantonsspital St. Gallen, St. Gallen, Switzerland.
- 700 1_
- $a Gottfredsson, M $u Faculty of Medicine, School of Health Sciences, University of Iceland, Reykjavik, Iceland and Landspitali University Hospital, Reykjavík, Iceland.
- 700 1_
- $a Khromova, I $u Centre for HIV/AIDS and infectious diseases, Kaliningrad, Russian Federation.
- 700 1_
- $a Jilich, D $u Department of Infectious and Tropical Diseases, First Faculty of Medicine, Charles University and Na Bulovce Hospital, Prague, Czech Republic.
- 700 1_
- $a Flisiak, R $u Department of Infectious Diseases and Hepatology, Medical University of Bialystok, Bialystok, Poland.
- 700 1_
- $a Smidt, J $u Ida-Viru Central Hospital, Kohtla-Jarve.
- 700 1_
- $a Rozentale, B $u Infectology Center of Latvia, Riga, Latvia.
- 700 1_
- $a Radoi, R $u Dr. Victor Babes Hospital, Bucureşti, Romania.
- 700 1_
- $a Losso, M H $u Hospital J.M. Ramos Mejia, Buenos Aires, Argentina.
- 700 1_
- $a Lundgren, J D $u Rigshospitalet, University of Copenhagen, Copenhagen, Denmark.
- 700 1_
- $a Mocroft, A $u Centre for Clinical Research, Modelling and Epidemiology, Research Department of Infection and Population Health, Institute for Global Health, University College London Medical School, Royal Free Campus, London, UK.
- 700 1_
- $a ,
- 773 0_
- $w MED00007240 $t HIV medicine $x 1468-1293 $g Roč. 19, č. 2 (2018), s. 102-117
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/28984429 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190405 $b ABA008
- 991 __
- $a 20190409152051 $b ABA008
- 999 __
- $a ok $b bmc $g 1392376 $s 1051371
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 19 $c 2 $d 102-117 $e 20171006 $i 1468-1293 $m HIV medicine $n HIV Med $x MED00007240
- LZP __
- $a Pubmed-20190405
